Knight Therapeutics (TSE:GUD) Hits New 12-Month High at $5.95

Knight Therapeutics Inc. (TSE:GUD)’s share price hit a new 52-week high during mid-day trading on Monday . The company traded as high as C$5.95 and last traded at C$5.88, with a volume of 4397 shares. The stock had previously closed at C$5.91.

Analysts Set New Price Targets

Several research analysts have commented on the company. Royal Bank of Canada boosted their target price on Knight Therapeutics from C$6.50 to C$7.00 and gave the stock an “outperform” rating in a research note on Friday, March 22nd. Raymond James lifted their price objective on shares of Knight Therapeutics from C$7.00 to C$7.50 and gave the company an “outperform” rating in a report on Wednesday, March 6th. Finally, Stifel Nicolaus increased their price objective on shares of Knight Therapeutics from C$5.25 to C$5.40 and gave the company a “hold” rating in a research note on Wednesday, May 1st.

Knight Therapeutics Price Performance

The company has a current ratio of 3.20, a quick ratio of 1.79 and a debt-to-equity ratio of 9.25. The stock has a market capitalization of C$598.93 million, a PE ratio of -36.94, a PEG ratio of -1,013.50 and a beta of 0.49. The firm’s 50-day moving average price is C$5.53 and its 200-day moving average price is C$5.34.

Knight Therapeutics (TSE:GUD) last issued its earnings results on Thursday, March 21st. The company reported C($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C($0.05). Knight Therapeutics had a negative return on equity of 2.14% and a negative net margin of 5.13%. The business had revenue of C$74.20 million for the quarter, compared to the consensus estimate of C$78.37 million. On average, equities analysts forecast that Knight Therapeutics Inc. will post 0.0602815 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Sime Armoyan purchased 351,000 shares of the stock in a transaction dated Monday, March 25th. The shares were purchased at an average cost of C$5.25 per share, with a total value of C$1,842,750.00. Insiders own 46.44% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.